Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy

S. J. You, D. E. Jung, HeungDong Kim, H. S. Lee, hoonchul kang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of adjunctive prednisolone therapy in children with cryptogenic epileptic encephalopathy, other than infantile spasms, and to determine its prognosis. Methods: Prednisolone, 2 mg/kg per day for 6 weeks, tapered for a further 2 weeks, was given in combination with previously prescribed antiepileptic drugs. A retrospective assessment of 41 children thus treated included measurements of seizure frequency, electroencephalographic findings, global assessments of cognitive function, and adverse drug events. Long-term patient prognoses over a mean follow-up period of 3 years and 5 months (range, 14-90 months) were also examined. Results: Of 41 patients, 32 had Lennox-Gastaut syndrome, 4 had Doose syndrome, 1 had Otahara syndrome, 2 had Landau-Kleffner syndrome, and 2 had other unspecified generalized epilepsies. After prednisolone therapy, 73% (30/41) of patients showed a reduction in seizure frequency of >50%, and 59% (24/41) became seizure free. However, only seven patients (four with Lennox-Gastaut syndrome, two with Doose syndrome, and one with unspecified generalized epilepsy) who became seizure free remained free of seizures at the time of the final follow-up. Electroencephalographic findings and global assessments of cognitive function correlated well with seizure outcomes. No significant demographic factors influenced the efficacy of prednisolone or patient prognoses after prednisolone tapering. Most adverse events were transient, or were tolerated well with conservative management, with maintenance of the medication. Conclusion: Prednisolone therapy may be a safe and effective adjunct in patients with cryptogenic epileptic encephalopathies, but the high relapse rate is of concern.

Original languageEnglish
Pages (from-to)314-320
Number of pages7
JournalEuropean Journal of Paediatric Neurology
Volume12
Issue number4
DOIs
Publication statusPublished - 2008 Jul 1

Fingerprint

Prednisolone
Epilepsy
Seizures
Pediatrics
Generalized Epilepsy
Brain Diseases
Cognition
Landau-Kleffner Syndrome
Therapeutics
Infantile Spasms
Drug-Related Side Effects and Adverse Reactions
Anticonvulsants
Maintenance
Demography
Safety
Recurrence

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology

Cite this

@article{18c1800445ee425abcb3a490de72095d,
title = "Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy",
abstract = "Purpose: To evaluate the efficacy and safety of adjunctive prednisolone therapy in children with cryptogenic epileptic encephalopathy, other than infantile spasms, and to determine its prognosis. Methods: Prednisolone, 2 mg/kg per day for 6 weeks, tapered for a further 2 weeks, was given in combination with previously prescribed antiepileptic drugs. A retrospective assessment of 41 children thus treated included measurements of seizure frequency, electroencephalographic findings, global assessments of cognitive function, and adverse drug events. Long-term patient prognoses over a mean follow-up period of 3 years and 5 months (range, 14-90 months) were also examined. Results: Of 41 patients, 32 had Lennox-Gastaut syndrome, 4 had Doose syndrome, 1 had Otahara syndrome, 2 had Landau-Kleffner syndrome, and 2 had other unspecified generalized epilepsies. After prednisolone therapy, 73{\%} (30/41) of patients showed a reduction in seizure frequency of >50{\%}, and 59{\%} (24/41) became seizure free. However, only seven patients (four with Lennox-Gastaut syndrome, two with Doose syndrome, and one with unspecified generalized epilepsy) who became seizure free remained free of seizures at the time of the final follow-up. Electroencephalographic findings and global assessments of cognitive function correlated well with seizure outcomes. No significant demographic factors influenced the efficacy of prednisolone or patient prognoses after prednisolone tapering. Most adverse events were transient, or were tolerated well with conservative management, with maintenance of the medication. Conclusion: Prednisolone therapy may be a safe and effective adjunct in patients with cryptogenic epileptic encephalopathies, but the high relapse rate is of concern.",
author = "You, {S. J.} and Jung, {D. E.} and HeungDong Kim and Lee, {H. S.} and hoonchul kang",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.ejpn.2007.09.003",
language = "English",
volume = "12",
pages = "314--320",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy. / You, S. J.; Jung, D. E.; Kim, HeungDong; Lee, H. S.; kang, hoonchul.

In: European Journal of Paediatric Neurology, Vol. 12, No. 4, 01.07.2008, p. 314-320.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and prognosis of a short course of prednisolone therapy for pediatric epilepsy

AU - You, S. J.

AU - Jung, D. E.

AU - Kim, HeungDong

AU - Lee, H. S.

AU - kang, hoonchul

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Purpose: To evaluate the efficacy and safety of adjunctive prednisolone therapy in children with cryptogenic epileptic encephalopathy, other than infantile spasms, and to determine its prognosis. Methods: Prednisolone, 2 mg/kg per day for 6 weeks, tapered for a further 2 weeks, was given in combination with previously prescribed antiepileptic drugs. A retrospective assessment of 41 children thus treated included measurements of seizure frequency, electroencephalographic findings, global assessments of cognitive function, and adverse drug events. Long-term patient prognoses over a mean follow-up period of 3 years and 5 months (range, 14-90 months) were also examined. Results: Of 41 patients, 32 had Lennox-Gastaut syndrome, 4 had Doose syndrome, 1 had Otahara syndrome, 2 had Landau-Kleffner syndrome, and 2 had other unspecified generalized epilepsies. After prednisolone therapy, 73% (30/41) of patients showed a reduction in seizure frequency of >50%, and 59% (24/41) became seizure free. However, only seven patients (four with Lennox-Gastaut syndrome, two with Doose syndrome, and one with unspecified generalized epilepsy) who became seizure free remained free of seizures at the time of the final follow-up. Electroencephalographic findings and global assessments of cognitive function correlated well with seizure outcomes. No significant demographic factors influenced the efficacy of prednisolone or patient prognoses after prednisolone tapering. Most adverse events were transient, or were tolerated well with conservative management, with maintenance of the medication. Conclusion: Prednisolone therapy may be a safe and effective adjunct in patients with cryptogenic epileptic encephalopathies, but the high relapse rate is of concern.

AB - Purpose: To evaluate the efficacy and safety of adjunctive prednisolone therapy in children with cryptogenic epileptic encephalopathy, other than infantile spasms, and to determine its prognosis. Methods: Prednisolone, 2 mg/kg per day for 6 weeks, tapered for a further 2 weeks, was given in combination with previously prescribed antiepileptic drugs. A retrospective assessment of 41 children thus treated included measurements of seizure frequency, electroencephalographic findings, global assessments of cognitive function, and adverse drug events. Long-term patient prognoses over a mean follow-up period of 3 years and 5 months (range, 14-90 months) were also examined. Results: Of 41 patients, 32 had Lennox-Gastaut syndrome, 4 had Doose syndrome, 1 had Otahara syndrome, 2 had Landau-Kleffner syndrome, and 2 had other unspecified generalized epilepsies. After prednisolone therapy, 73% (30/41) of patients showed a reduction in seizure frequency of >50%, and 59% (24/41) became seizure free. However, only seven patients (four with Lennox-Gastaut syndrome, two with Doose syndrome, and one with unspecified generalized epilepsy) who became seizure free remained free of seizures at the time of the final follow-up. Electroencephalographic findings and global assessments of cognitive function correlated well with seizure outcomes. No significant demographic factors influenced the efficacy of prednisolone or patient prognoses after prednisolone tapering. Most adverse events were transient, or were tolerated well with conservative management, with maintenance of the medication. Conclusion: Prednisolone therapy may be a safe and effective adjunct in patients with cryptogenic epileptic encephalopathies, but the high relapse rate is of concern.

UR - http://www.scopus.com/inward/record.url?scp=43749097619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43749097619&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2007.09.003

DO - 10.1016/j.ejpn.2007.09.003

M3 - Article

VL - 12

SP - 314

EP - 320

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 4

ER -